Ex­elix­is li­cens­es small mol­e­cule from In­sil­i­co for $80M up­front; Ver­tex buys GPCR from Septer­na

Ex­elix­is is buy­ing in­to a can­cer drug can­di­date dis­cov­ered by gen­er­a­tive AI from In­sil­i­co Med­i­cine, the two com­pa­nies an­nounced Tues­day. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.